Navigation Links
New Data Demonstrates 5-FU Personalized Chemotherapy Management (PCM(R)) Assay Provides Similar Performance to More Complicated Liquid Chromatography-Mass Spectrometry (LC-MS/MS)
Date:6/23/2008

000 new cases diagnosed each year, resulting in approximately 500,000 deaths annually.(iii) In the U.S., it is the third leading cause of cancer mortality, and in 2008, nearly 50,000 deaths will be attributed to this disease.(i) Its incidence rate is strongly correlated with age. Data from industrialized countries demonstrate that the incidence of colorectal cancer rises three-fold between the ages of 60 and 80 years.(ii)

About Saladax

Saladax Biomedical is pioneering the development of novel, rapid, and cost-effective immunoassays that will enable routine blood-level monitoring of anti-cancer drugs to become the standard of care in treating cancer patients. With Personalized Chemotherapy Management (PCM), oncologists will be able to adjust the administered dose based on each patient's individual drug level, leading to reduced toxicity, improved outcome and lower cancer care costs. Saladax is headquartered at the business incubator of the Ben Franklin Technology Partners (BFTP) of Northeastern Pennsylvania on the campus of Lehigh University in Bethlehem. The 5-FU PCM test will be available to U.S. clinicians later this year through a major reference laboratory.

References

(i) American Cancer Society, "What are the Key Statistics for Colorectal Cancer?," March 5, 2008, http://www.cancer.org/docroot/cri/content/cri_2_4_1x_what_are_the_key_stati sti cs_for_colon_and_rectum_cancer.asp (April 22, 2008).

(ii) Gamelin, E, Delva, R, Jacob, J, et al: "Individual fluorouracil dose adjustment based on pharmacokinetic follow-up compared with conventional dosage: Results of a multicenter randomized trial of patients with metastatic colorectal cancer." J. Clin Oncol 13:2099-2105, 2008.

(iii) World Health Organization, "World Cancer Report." April 3, 2003, '/>"/>

SOURCE Saladax Biomedical
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Pivotal Pulmonary Arterial Hypertension Study Published in The Lancet Concludes That Bosentan (Tracleer(R)) Demonstrates Benefits in Patients With Mildly Symptomatic WHO Functional Class II Disease
2. Phase 1/2 Trial of Motexafin Gadolinium Plus Antibody Targeted Radiation Therapy Demonstrates High Complete Response Rate in Patients With Non-Hodgkins Lymphoma
3. Micromets BiTE Antibody Blinatumomab (MT103/MEDI-538) Demonstrates Durable Responses in Patients with Relapsed Non-Hodgkins Lymphoma
4. Further Clinical Testing of BZL101 in Advanced Breast Cancer Demonstrates Favorable Efficacy and Toxicity Profiles
5. Video: Major Independent Trial Demonstrates Significant Anticancer Benefit of Zometa(R) in Women With Early-Stage Breast Cancer
6. Phase I/II Study of Targeted Gene Delivery In Vivo - Intravenous Infusions of REXIN-G - Demonstrates Dose-Dependent Anti-Tumor Activity Without Toxicity in Patients With Progressive Chemo-Resistant Bone and Soft Tissue Sarcoma (ASCO 2008)
7. Treprostinil Data Presented at American Thoracic Society Conference Demonstrates Significant Clinical Progress in All Four Routes of Administration
8. Tioga Pharmaceuticals Asimadoline Demonstrates Positive Results in a Phase 2b Clinical Trial for the Treatment of Irritable Bowel Syndrome
9. New Study Demonstrates ACTEMRA(R) (tocilizumab) Inhibits Progression of Joint Damage in Rheumatoid Arthritis Patients
10. Study Demonstrates Lexapro(R) Significantly Improves Depression Symptoms in Adolescents
11. Clinical Data Demonstrates 5-Year Efficacy and Safety of Aquamid(R) in Facial Augmentation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/4/2015)... 4, 2015  Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: ... of the Phase II proof of concept clinical ... as a monotherapy in the treatment of chronic ... highly significant and clinically meaningful improvement from baseline ... measured on a 100mm unit Visual Analog Scale ...
(Date:3/4/2015)... March 4, 2015 Asterias Biotherapeutics, Inc. (NYSE ... field of regenerative medicine, today announced that Pedro ... The Opening Bell ® of the New York ... began trading as an NYSE MKT listed company on ... Exchange is a trusted partner to Asterias Biotherapeutics, and ...
(Date:3/4/2015)... 2015 InfuSystem Holdings, Inc. (NYSE MKT: INFU), ... services for the U.S. healthcare industry, today announced that ... financial results on Monday, March 9, 2015 after the ... a conference call for investors on Monday, March 9, ... quarter and full year 2014 performance and results.  To ...
Breaking Medicine Technology:Vanda Pharmaceuticals Announces Tradipitant Phase II Proof of Concept Study Results for Chronic Pruritus in Atopic Dermatitis 2Vanda Pharmaceuticals Announces Tradipitant Phase II Proof of Concept Study Results for Chronic Pruritus in Atopic Dermatitis 3Vanda Pharmaceuticals Announces Tradipitant Phase II Proof of Concept Study Results for Chronic Pruritus in Atopic Dermatitis 4Vanda Pharmaceuticals Announces Tradipitant Phase II Proof of Concept Study Results for Chronic Pruritus in Atopic Dermatitis 5Vanda Pharmaceuticals Announces Tradipitant Phase II Proof of Concept Study Results for Chronic Pruritus in Atopic Dermatitis 6Vanda Pharmaceuticals Announces Tradipitant Phase II Proof of Concept Study Results for Chronic Pruritus in Atopic Dermatitis 7Asterias Biotherapeutics to Ring Opening Bell at New York Stock Exchange 2Asterias Biotherapeutics to Ring Opening Bell at New York Stock Exchange 3
(Date:3/4/2015)... When people talk about venues being the ... across numerous genres, the Houston Rodeo will be ... during the annual livestock show and rodeo, one popular band ... activities being held at the event. The 2015 show will ... will try and get the festival its largest attendance ever. ...
(Date:3/4/2015)... Cook For Your Life (CFYL), a New ... to people touched by cancer, is launching its first ... by founder Ann Ogden, will be facilitated by Drexel ... partnership will expand the program from its base. , ... After going through her own cancer treatments, Ogden realized ...
(Date:3/4/2015)... New York (PRWEB) March 04, 2015 ... reviewing the cardiovascular risks potentially associated with low testosterone ... Administration (FDA) announced that it will now require manufacturers ... increase their risk for heart attacks and strokes. In ... 2015, the agency also stated that it was requiring ...
(Date:3/4/2015)... Optrix by Body Glove ” was featured on NewsWatch ... a look at the latest and coolest technology products ... reporter for NewsWatch and a technology expert, conducted the ... an ultra-rugged, waterproof case with an interchangeable lens system. ... the Consumer Electronics Show in Las Vegas every year. ...
(Date:3/4/2015)... 04, 2015 The popular all-natural supplement ... new L-Style Revolution™ Program. The customized program provides a ... of all health and fitness levels to follow and ... than traditional methods. , “We’re really proud to announce ... based on award winning techniques to help people according ...
Breaking Medicine News(10 mins):Health News:Cheap Houston Rodeo Tickets: Ticket Down Slashes Houston Rodeo Tickets for John Legend, Pitbull, Alan Jackson, Tim McGraw, Zac Brown Band, Fall Out Boy & Miranda Lambert 2Health News:Cheap Houston Rodeo Tickets: Ticket Down Slashes Houston Rodeo Tickets for John Legend, Pitbull, Alan Jackson, Tim McGraw, Zac Brown Band, Fall Out Boy & Miranda Lambert 3Health News:Drexel University and Cook for Your Life Team Up 2Health News:Drexel University and Cook for Your Life Team Up 3Health News:Drexel University and Cook for Your Life Team Up 4Health News:Drexel University and Cook for Your Life Team Up 5Health News:Testosterone Lawsuit Attorneys at Bernstein Liebhard LLP Comment on FDA Mandate For New Cardiovascular Warnings on Low T Therapy Drugs 2Health News:Testosterone Lawsuit Attorneys at Bernstein Liebhard LLP Comment on FDA Mandate For New Cardiovascular Warnings on Low T Therapy Drugs 3Health News:Testosterone Lawsuit Attorneys at Bernstein Liebhard LLP Comment on FDA Mandate For New Cardiovascular Warnings on Low T Therapy Drugs 4Health News:A Waterproof Phone Case with an Interchangeable Lens System was Featured on NewsWatch Television on January 30, 2015 2Health News:The Makers of Liporidex, The Popular Sports Nutrition Supplement Brand, Launches Its New L-Style Revolution™ Diet & Exercise Program That Promises Turbo Charged Results 2
... adults of industrialized countries is approximately 10% and is ... is scarce. , A research article published ... Gastroenterology addresses this problem. The team lead by Dr. ... Canada, has reviewed the rate of gallstone disease and ...
... means of microsatellite markers has become an effective way ... candidate tumor suppressor genes. In a previous study, it ... frequencies, which indicated that the region might harbor the ... contained so many genes that it was inconvenient to ...
... Intraductal papillary neoplasm of the bile duct (IPN-B) is ... is a new definition of a tumor with papillary ... authors reported a case of IPN-B with interesting histopathological ... the diagnosis of bile duct dilatation due to the ...
... ARNA ) today announced it will report first ... on Wednesday, May,7, 2008. That same afternoon, Jack Lief, ... Arena,s Vice President, Finance,and Chief Financial Officer, will host ... Pacific Time) to discuss the first quarter 2008,financial results ...
... 30 The following is an,editorial from The Wall ... Committee:, [J]ohn McCain delivered another speech yesterday on ... could lead to some of the most,constructive changes to ... for his candidacy if Mr. McCain is making space ...
... FRAZER, Pa., April 30 Cephalon, Inc. (Nasdaq:,CEPH) ... Executive Vice,President and General Counsel. In this position, ... company, including those relating to commercial,and financial transactions, ... directly to Chairman and CEO, Frank,Baldino Jr., Ph.D., ...
Cached Medicine News:Health News:A patient who was diagnosed as IPN-B without hepatolithiasis? 2Health News:Arena Pharmaceuticals to Report First Quarter 2008 Financial Results and to Host Conference Call and Webcast on Wednesday, May 7, 2008 2Health News:Arena Pharmaceuticals to Report First Quarter 2008 Financial Results and to Host Conference Call and Webcast on Wednesday, May 7, 2008 3Health News:RNC: McCain's Progress 2Health News:Cephalon Appoints Gerald J. Pappert as General Counsel 2Health News:Cephalon Appoints Gerald J. Pappert as General Counsel 3
AnkleWALKER™ Shorter uprights and circumferential plastic shell inhibit foot and ankle motion. Designed to provide comfortable stability for acute ankle sprains, soft tissue injuries, stress an...
... The FoamWalker is a cost-effective walking ... support. It has a lightweight, durable, semi-rigid ... protection. The shell's rocker sole helps reduce ... two aircells for compression and support at ...
... VACOPED is a revolutionary cast replacement ... the lower leg and foot. , ... patient's anatomy and in conjunction with a ... the general time of fracture or rupture ...
... of controlled compression and cold, the Calf ... anatomically designed cuff provides complete calf coverage ... as a single cuff, or with a ... disk). The Cooler is available separately and ...
Medicine Products: